CADTH Canadian Drug Expert Committee recommendation: Safinamide (Onstryv -- Valeo Pharma Inc.) indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD) in patients experiencing "OFF" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD.

The CADTH Canadian Drug Expert Committee (CDEC) recommends that safinamide should not be reimbursed as add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic PD in patients experiencing "OFF" episodes while on a stable dose of levodopa

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH March 2020, 2020
Edition:	Version: 1.0
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Parkinson Disease / Drug Therapy Canada Drug Therapy, Combination Antiparkinson Agents / Therapeutic Use Monoamine Oxidase Inhibitors / Therapeutic Use Alanine / Therapeutic Use
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK564245
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa